Evaluation of Therapeutic Response Under Biologic Therapy in Patients with Rheumatoid Arthritis
Abstract
Biotherapy has revolutionized the therapeutic management of rheumatoid arthritis (RA). The objective of the study was to evaluate and compare the efficacy and tolerance of biological disease modifying antirheumatic drugs (bDMARDs) and conventional disease modifying antirheumatic drugs ( cDMARDs) used in RA.
It was a retrospective study covering 13 years at the level of the immunology unit of the UHU Hassiba Ben Bouali Blida and functional rehabilitation service of the CHU Frantz Fanon Blida. We identified 1866 records of patients with RA, 75 receiving biotherapy and 71 receiving conventional treatment. The therapeutic response was evaluated by the DAS 28-ESR (disease activity score based on erythrocyte sedimentation rate) and interpreted according to the EULAR (European league against rheumatism) judgements criteria.
A female predominance of 83%, the average age of RA patients was 49.3 ±13.42 years, the mean starting DAS28-ESR was 5.625± 1.4. 84% of patients initially received MTX (methotrexate) on the front line, the decrease in DAS28-ESR was non- significant, with patients exhibiting intolerance (41%), and (45%) ineffectiveness. The introduction of biotherapy mainly Actemra allowed a decrease of DAS28-ESR of - 1.842±0.3812, a significant decrease according to the criteria of the EULAR. Humira had an adverse efficacy and tolerance profile (including the occurrence of severe adverse effects (AEs)).
In conclusion, biotherapy is more effective than conventional treatments, while in terms of tolerance data are insufficient to make a judgment on it.
Keywords: Rheumatoid arthritis – Biotherapy.
Keywords:
Rheumatoid arthritis, BiotherapyDOI
https://doi.org/10.22270/jddt.v14i2.6404References
Radu, A.-F.; Bungau, S.G. Management of Rheumatoid Arthritis: An Overview. Cells 2021, 10, 2857. https://doi.org/10.3390/cells10112857
Scherer HU, Häupl T, Burmester GR. The etiology of rheumatoid arthritis. J Auto-immune. 2020 Jun;110:102400. https://doi.org/10.1016/j.jaut.2019.102400
Boissier M-C, Biton J, Semerano L, Decker P, Bessis N. L’origine de la polyarthrite rhumatoïde. Revue du Rhumatisme. 2019;86:A19-A24. http://dx.doi.org/10.1016/S1169-8330(19)30353-9
Benjamin O, Goyal A, Lappin SL. Disease modifying anti-rheumatic drugs (DMARD). 2018. PMID: 29939640.
Bouaddi I, El Badri D, Hassani A, Bahouque H, Rkain H, Allali F, et al. Les critères d’évaluation de la polyarthrite rhumatoïde. Rev Mar Rhum. 2012;19:19-23. http://dx.doi.org/10.24398/a.122.2012
Hmamouchi I, Combe B, Fautrel B, Rincheval N, Lukas C. Prévalence et concordance de la rémission précoce et prolongée évaluée par différents indices validés de la cohorte d’arthrites débutantes «ESPOIR». Revue du Rhumatisme. 2015;82(1):47-53. https://doi.org/10.1016/j.rhum.2014.04.001
Gaujoux-Viala C, Gossec L, Cantagrel A, Dougados M, Fautrel B, Mariette X, et al. Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. Revue du rhumatisme. 2014;81(4):303-12. https://doi.org/10.1016/j.rhum.2014.04.009
Hua C, Daien CI, Combe B, Landewe R. Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. RMD open. 2017;3(1):e000406. https://doi.org/10.1136/rmdopen-2016-000406
Daien C, Hua C, Gaujoux-Viala C, Cantagrel A, Dubremetz M, Dougados M, et al. Actualisation des Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. Revue du rhumatisme. 2019;86(1):8-24. https://doi.org/10.1016/j.rhum.2018.09.008
Brahem M, Sarraj R, Grassa R, Amani B, Hachfi H, Younes M. Les facteurs prédictifs de l’intolérance au méthotrexate au cours de la polyarthrite rhumatoïde. Revue du Rhumatisme. 2021;88:A298-A9. https://doi.org/10.1016/j.rhum.2021.10.510
Oulkadi L, Rostom S, Hmamouchi I, Binoune IE, Amine B, Abouqal R, Achemlal L, Allali F, Bouchti IE, Maghraoui AE, Ghozlani I, Hassikou H, Harzy T, Ichchou L, Mkinsi O, Niamane R, Bahiri R. Therapeutic Maintenance Level of Methotrexate in Rheumatoid Arthritis: A RBSMR Study. Mediterr J Rheumatol. 2022 Jun 30;33(2):224-231. https://doi.org/10.31138%2Fmjr.33.2.224
Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nature Reviews Rheumatology. 2016;12(12):731-42. https://doi.org/10.1038/nrrheum.2016.175
Inotai A, Rojkovich B, Fülöp A, Jászay E, Ágh T, Mészáros Á. Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis. Rheumatology international. 2012;32:963-9. https://doi.org/10.1007/s00296-010-1721-x
Pers Y-M, Fortunet C, Constant E, Lambert J, Godfrin-Valnet M, De Jong A, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology. 2014;53(1):76-84. https://doi.org/10.1093/rheumatology/ket301
Codreanu C, Mogosan C, Ionescu R, Ancuta I, Opris D. Biologic therapy in rheumatoid arthritis: results from the Romanian registry of rheumatic diseases one year after initiation. Farmacia. 2014;62(6):1089-96. DOI: 10.37897/RJR.2020.2.2.
Divonne MdlF, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers. Joint Bone Spine. 2017;84(2):133-40. https://doi.org/10.1016/j.jbspin.2016.02.028
Cacciapaglia F, Venerito V, Stano S, Fornaro M, Lopalco G, Iannone F. Comparison of adalimumab to other targeted therapies in rheumatoid arthritis: results from systematic literature review and meta-analysis. Journal of Personalized Medicine. 2022;12(3):353. https://doi.org/10.3390/jpm12030353
Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo RM, et al. Taux de rétention de l’adalimumab, de l’étanercept et de l’infliximab en 1re ou 2e ligne de biothérapie chez les patients atteints de polyarthrite rhumatoïde en pratique courante. Revue du rhumatisme. 2014;81(6):483-90. https://doi.org/10.1016/j.rhum.2014.07.001
Hagege O, Lequerre T, Marcelli C, Varin R, Alcaix D, Weber A, et al. AB1615 EVALUATION OF THE NOCEBO EFFECT WHEN SWITCHING FROM THE ORIGINATOR MOLECULE TO A BIOSIMILAR IN A NORMANDY RETROSPECTIVE COHORT OF PATIENTS WITH INFLAMMATORY RHEUMATISM TREATED WITH ETANERCEPT OR ADALIMUMAB (BIONORIC STUDY). BMJ Publishing Group Ltd; 2023. https://doi.org/10.1136/annrheumdis-2023-eular.4416
Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet (London, England). 2013;381(9877):1541-50. https://doi.org/10.1016/s0140-6736(13)60250-0
Ediriweera A, Aung T, Savanovic-Abel O. AB0408 DESCRIPTIVE STUDY ON USE OF BIOSIMILARS IN RHEUMATOID ARTHRITIS IN UNIVERSITY HOSPITALS PLYMOUTH, UNITED KINGDOM. BMJ Publishing Group Ltd; 2023. https://doi.org/10.1136/annrheumdis-2023-eular.2165
Lechat P. Médicaments biosimilaires: enjeux réglementaires et impacts médicoéconomiques. Bulletin de l'Académie Nationale de Médecine. 2020;204(8):877-83. https://doi.org/10.1016%2Fj.banm.2020.07.050
Akasbi N, Mounir A, Bakale FEO, El Fakir S, Harzy T. TOCILIZUMAB: EFFICACITE ET TOLERANCE DANS LA POLYARTHRITE RHUMATOÏDE EN PRATIQUE COURANTE. Integrative Journal of Medical Sciences. 2019;6:1-5. http://dx.doi.org/10.15342/ijms.v6ir.253
Genovese MC, Glover J, Greenwald M, Porawska W, El Khouri EC, Dokoupilova E, et al. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, phase III, double-blind study, and its open-label extension. Arthritis research & therapy. 2019;21(1):1-12. https://doi.org/10.1186/s13075-019-2046-0
Montero-Vilchez T, Cuenca-Barrales C, Rodriguez-Tejero A, Martinez-Lopez A, Arias-Santiago S, Molina-Leyva A. Switching from adalimumab originator to biosimilar: clinical experience in patients with hidradenitis suppurativa. Journal of Clinical Medicine. 2022;11(4):1007. https://doi.org/10.3390/jcm11041007
Wu Y-F, Shin Y-C, Yang C-H, Huang Y-H. Efficacy and safety of etanercept in the treatment of recalcitrant psoriasis: An open-label, retrospective, observational study in Taiwan. Dermatologica Sinica. 2013;31(2):49-53. http://dx.doi.org/10.1016/j.dsi.2012.09.001
Aouatef BF, Zohra GBF. Médicaments biosimilaires: entre évolution de la règlementation et… bon sens. Algerian Journal of Health Sciences. 2019;1(01):54-61.
Amgevita January 18, 2023 [Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/amgevita
Solymbic 2019 [Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/solymbic.
Goel N, Chance K. Biosimilars in rheumatology: understanding the rigor of their development. Rheumatology. 2017;56(2):187-97. https://doi.org/10.1093/rheumatology/kew206
Published



How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).